Ascentage Pharma Group International (AAPG)
NASDAQ: AAPG · Real-Time Price · USD
28.78
+0.89 (3.19%)
At close: Jan 9, 2026, 4:00 PM EST
28.78
0.00 (0.00%)
After-hours: Jan 9, 2026, 4:10 PM EST
AAPG Employees
Ascentage Pharma Group International had 567 employees as of December 31, 2024. The number of employees decreased by 16 or -2.74% compared to the previous year.
Employees
567
Change (1Y)
-16
Growth (1Y)
-2.74%
Revenue / Employee
$96,163
Profits / Employee
-$285,386
Market Cap
2.59B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 567 | -16 | -2.74% |
| Dec 31, 2023 | 583 | 3 | 0.52% |
| Dec 31, 2022 | 580 | -33 | -5.38% |
| Dec 31, 2021 | 613 | 180 | 41.57% |
| Dec 31, 2020 | 433 | 23 | 5.61% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AAPG News
- 4 weeks ago - ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP - GlobeNewsWire
- 4 weeks ago - ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60% - GlobeNewsWire
- 4 weeks ago - ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment - GlobeNewsWire
- 4 weeks ago - ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances - GlobeNewsWire
- 4 weeks ago - Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting - GlobeNewsWire
- 5 weeks ago - Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA - GlobeNewsWire
- 6 weeks ago - Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature's Signal Transduction and Targeted Therapy - GlobeNewsWire
- 7 weeks ago - Ascentage Pharma to Participate in Three Upcoming Investor Conferences in December 2025 - GlobeNewsWire